Anne Bénard-Laribière1,2, Pernelle Noize2,3,4, Elodie Pambrun1,2, Fabienne Bazin1,2, Hélène Verdoux1,2,5, Marie Tournier1,2,5, Bernard Bégaud1,2,3, Antoine Pariente1,2,3,4. 1. Univ. Bordeaux, U1219, Bordeaux, France. 2. Inserm U1219, Bordeaux Population Health Research Center, Pharmacoepidemiology research team, Bordeaux, France. 3. CHU Bordeaux, Service de Pharmacologie Médicale, Bordeaux, France. 4. CIC Bordeaux, CIC1401, Bordeaux, France. 5. Centre Hospitalier Charles Perrens, Bordeaux, France.
Abstract
PURPOSE: To study trends in incident use of benzodiazepines in France between 2006 and 2012. METHODS: A cross-sectional study repeated yearly was conducted using data from the French national healthcare insurance system. New benzodiazepine users were defined as users without any benzodiazepine dispensing in the year prior to the first dispensing of benzodiazepine in each year. Relative changes in incidence of use were calculated with the year 2006 as reference; confidence intervals for changes were estimated using the bootstrap method. RESULTS: Over the study period, the incident use of benzodiazepines decreased from 6.2% to 5.9%; this corresponded to a 5.1% decrease (95%CI: -6.8% to -4.2%) for 2012 compared to 2006. The decrease mainly concerned hypnotics (-15.5%; -21.2% to -15.3%) and appeared more pronounced in people aged 18-44 years. Incident use of anxiolytics remained stable overall during the period (4.0% of the population). Within anxiolytics, incident use of long half-life benzodiazepines (bromazepam, prazepam) decreased in favor of short half-life benzodiazepines (alprazolam, oxazepam). This change concerned patients aged 65-79 and patients aged 80 years and over. Nevertheless, in 2012, nearly one third of incident users aged 65 years and over started a treatment with a long half-life benzodiazepine, mostly bromazepam. CONCLUSIONS: A limited decrease in incident benzodiazepine use was observed in France between 2006 and 2012 that concerned only hypnotics. Although congruent with recommendations, this improvement appears insufficient with regard to the level of exposure to these drugs in France. New actions especially targeting anxiolytic benzodiazepine use should be undertaken to consolidate these results.
PURPOSE: To study trends in incident use of benzodiazepines in France between 2006 and 2012. METHODS: A cross-sectional study repeated yearly was conducted using data from the French national healthcare insurance system. New benzodiazepine users were defined as users without any benzodiazepine dispensing in the year prior to the first dispensing of benzodiazepine in each year. Relative changes in incidence of use were calculated with the year 2006 as reference; confidence intervals for changes were estimated using the bootstrap method. RESULTS: Over the study period, the incident use of benzodiazepines decreased from 6.2% to 5.9%; this corresponded to a 5.1% decrease (95%CI: -6.8% to -4.2%) for 2012 compared to 2006. The decrease mainly concerned hypnotics (-15.5%; -21.2% to -15.3%) and appeared more pronounced in people aged 18-44 years. Incident use of anxiolytics remained stable overall during the period (4.0% of the population). Within anxiolytics, incident use of long half-life benzodiazepines (bromazepam, prazepam) decreased in favor of short half-life benzodiazepines (alprazolam, oxazepam). This change concerned patients aged 65-79 and patients aged 80 years and over. Nevertheless, in 2012, nearly one third of incident users aged 65 years and over started a treatment with a long half-life benzodiazepine, mostly bromazepam. CONCLUSIONS: A limited decrease in incident benzodiazepine use was observed in France between 2006 and 2012 that concerned only hypnotics. Although congruent with recommendations, this improvement appears insufficient with regard to the level of exposure to these drugs in France. New actions especially targeting anxiolytic benzodiazepine use should be undertaken to consolidate these results.
Authors: Jordan Guillot; Christopher T Rentsch; Kirsha S Gordon; Amy C Justice; Julien Bezin Journal: Pharmacoepidemiol Drug Saf Date: 2022-07-15 Impact factor: 2.732
Authors: Ruth Ann Marrie; John D Fisk; Randy Walld; James M Bolton; Jitender Sareen; Scott B Patten; Alexander Singer; Lisa M Lix; Carol A Hitchon; Renée El-Gabalawy; Alan Katz; James J Marriott; Charles N Bernstein Journal: Front Neurol Date: 2022-04-14 Impact factor: 4.086
Authors: Parker Magin; Amanda Tapley; Adrian J Dunlop; Andrew Davey; Mieke van Driel; Elizabeth Holliday; Simon Morgan; Kim Henderson; Jean Ball; Nigel Catzikiris; Katie Mulquiney; Neil Spike; Rohan Kerr; Simon Holliday Journal: J Gen Intern Med Date: 2018-07-23 Impact factor: 5.128
Authors: Inken Arnold; Kati Straube; Wolfgang Himmel; Stephanie Heinemann; Vivien Weiss; Laura Heyden; Eva Hummers-Pradier; Roland Nau Journal: BMC Pharmacol Toxicol Date: 2017-12-04 Impact factor: 2.483
Authors: Simon J C Davies; Binu Jacob; David Rudoler; Juveria Zaheer; Claire de Oliveira; Paul Kurdyak Journal: Ther Adv Psychopharmacol Date: 2017-12-05
Authors: Clarice S Madruga; Thales L Paim; Hamer N Palhares; Andre C Miguel; Luciana T S Massaro; Raul Caetano; Ronaldo R Laranjeira Journal: Braz J Psychiatry Date: 2018-10-11 Impact factor: 2.697
Authors: Anna Sidorchuk; Kayoko Isomura; Yasmina Molero; Clara Hellner; Paul Lichtenstein; Zheng Chang; Johan Franck; Lorena Fernández de la Cruz; David Mataix-Cols Journal: PLoS Med Date: 2018-08-07 Impact factor: 11.069